HUMAN RECOMBINANT ACE2 RECEPTOR
MULTISCREEN™ STABLE CELL LINES
1 vial (2 x 106) frozen cells
Cellbanker 2 (Amsbio 11891)
Expression vector containing full-length human ACE2 cDNA (GenBank Accession Number: NM_021804.1) with FLAG tag sequence at N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS, 250 ug/mL hygromycin
Stable for a minimum of 2 months in continuous culture
Background: Angiotensin converting enzyme (ACE2) receptors locate in the human oral pharynx and upper airway where the high replication rate of Corona virus happens more easily. ACE2 has been confirmed as the cause of SARS-CoV-2 internalization in concert with TMPRSS2 (transmembrane protease serin 2). TMPRSS2 facilitates ACEs cell entry by priming the spike S protein of the virus. Therapeutic strategies that focus on the biology of ACE2 and TMPRSS2 may become beneficial for the treatment of lung disease.
Application: Functional assays
Figure 1. Dose-dependent inhibition of protease activity, measured w ith fluorogenic peptide substrate specific to ACE2 Figure 2. Receptor expression on cell surface measured by flow cytometry (FACS) using anti-Flag antibody. Thin line: parental cells; thick line: receptor-expressing cells.
Liu et al. (2020) The science underlying COVID-19, Implications for the Cardiovascular System. Circulation. 2020;142:68–78. DOI: 10.1161/CIRCULATIONAHA. 120.047549
Hoffmann et al. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271–280, April 16, 2020
Zhang, et al. Angiotensin- converting enzyme 2 (ACE2) as a SARS- CoV-2 receptor: molecular mechanisms and potential therapeutic target. (2020). Intensive Care Med., 46, 586–5905.